SEC Form 4 · accession 0001127602-18-005553
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Young
Officer — Chief Operating Officer
Period of report
Feb 10, 2018
Accepted (ET)
Feb 13, 2018 · 4:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 10, 2018 | M | 908 | $0.00 | A | 16,237 | D | |
| Common Stock | Feb 10, 2018 | F | 425 | $79.32 | D | 15,812 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Feb 10, 2018 | M | 908 | D | — | — | Common Stock | 908 | 3,184 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F2The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.